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ABSTRACT

Objective In patients with non-ischaemic cardiomyopathy
and reduced left ventricular ejection fraction (LVEF),
normalisation of LVEF is associated with improved
outcomes. However, data on patients with ischaemic
cardiomyopathy and recovered LVEF are lacking. The goal
of this study was to assess the prognostic significance
of normalisation of the LVEF in patients with ischaemic
cardiomyopathy.
Methods/Results We performed a non-prespecified post
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hoc analysis of the Surgical Treatment for Ischaemic Heart
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Failure (STICH) trial to determine the association between
Accepted 22 February 2021
normalisation of LVEF (>50%) and mortality during follow-
up. Of the 1212 patients with LVEF <35% enroled in
the STICH trial, 932 underwent assessment of LVEF at 4
months and/or 2 years after enrolment. Among them, 18
patients experienced normalisation in LVEF at 4-month
follow-up and 35 patients experienced recovery in LVEF
at 2 years. Recovery of LVEF at 4 months and recovery
of LVEF at 2 years were not correlated. Recovery of LVEF
at 4 months was not associated with reduced all-cause
mortality in unadjusted analysis (log-rank test p=0.54) or
in Cox proportional hazards analysis (HR: 0.93; 95% CI:
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0.48 to 1.80; p=0.82). Ejection fraction recovery at 2 years
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was associated with a reduction in all-cause mortality,
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both in unadjusted analysis (log-rank test p=0.004) and in
and permissions. Published
the Cox proportional hazard model (HR: 0.41; 95% CI: 0.21
by BMJ.
to 0.80; p=0.009).
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INTRODUCTION
As management strategies for heart failure
with reduced ejection fraction (HFrEF)
continue to improve, more patients experience improvement in left ventricular ejection
fraction (LVEF) to a normal range (>50%).
Several studies have suggested that even
though recovery of LVEF typically does not
correspond to a true normalisation of myocardial function,1 2 it is associated with a marked
improvement in outcomes.2 3 However,

Key questions
What is already known about this subject?
►► Many patients with non-ischaemic cardiomyopathy

experience reverse left ventricular remodelling to
the point of regaining an ejection fraction in the normal range. This is associated with an improvement
in prognosis. In patients with ischaemic cardiomyopathy normalisation of left ventricular ejection fraction (LVEF) is much less common and its prognostic
significance is unclear.

What does this study add?
►► Through a non-
prespecified post-
hoc analysis

of patients enroled in the Surgical Treatment for
Ischaemic Heart Failure trial, we found that patients
with ischaemic cardiomyopathy can experience early or delayed normalisation in LVEF. The two events
are rare and are not correlated. Delayed normalisation in LVEF is associated with reduced mortality,
early normalisation is not.

How might this impact on clinical practice?
►► This study indicates that clinicians caring for pa-

tients with ischaemic cardiomyopathy and reduced
LVEF can interpret delayed normalisation in LVEF as
a positive prognostic marker but should interpret
early normalisation in LVEF with caution.

these analyses have focused on cohorts with
a majority, or exclusively, of patients with
heart failure of non-
ischaemic aetiology.3–7
In the landmark study that introduced the
concept of heart failure with recovered LVEF,
Basuray et al studied a cohort in which only
16% of patients had ischaemic cardiomyopathy (ICM).3 Other studies that focused on
outcomes in patients with normalised LVEF
included a percentage of patients with ICM
ranging from 0%6 7 to 35%.5
Epidemiological data suggest that the
timing and biology of reverse cardiac
remodelling and ‘apparent healing’ differs
depending on the aetiology of heart failure.8
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METHODS
Data source
The STICH dataset was obtained from the NHLBI under
a data use agreement. The Washington University Human
Research Protection Office granted this study an exemption from Institutional Review Board oversight due to the
de-identified nature of the data.
Study population
The rationale and methodology for patient selection
in the STICH trial have been described previously.13 In
brief, STICH was an international, multicentre, non-
blinded, randomised trial. Patients included in the study
had coronary artery disease, were eligible for coronary
artery bypass graft (CABG) surgery and had a LVEF ≤35%.
Patients were then randomised to one of three treatment
arms: optimal medical therapy (OMT), CABG plus OMT
or CABG plus OMT and surgical ventricular repair. For
this study, we analysed only patients randomised to the
CABG plus OMT or OMT alone (hypothesis 1).
Of the 1212 patients with LVEF ≤35% enroled in the
STICH trial and randomised to OMT or CABG plus OMT,
932 underwent echocardiographic assessment of LVEF at
4 months and/or 2 years, while 587 patients had LVEF
assessment at both time points. No assessment was done
at other times. A total of 267 subjects without recorded
ejection fraction (EF) were excluded. Two subjects with
baseline EF >50% were also excluded. There were also 11
patients with EF reported after date of death who were
excluded. We defined LVEF recovery as LVEF >50%. In
the STICH trial, LVEF was measured either via visual estimate or biplane method, and measurements obtained
with these two methods within this cohort were highly
correlated.14

the relationship between LVEF recovery at 4 months
and LVEF recovery at 2 years. Mortality was compared
between patients with recovered LVEF and patients
without recovered LVEF at 4 months or 2 years with
multivariate Cox proportional hazard models. Because
patients in the STICH trial did not have information
on recovery status between 4 months and 2 years, and
because most patients who recovered at 4 months did
not retain their recovery status (described in the Results
section), a time to recovery variable could not be accurately calculated. We therefore decided against including
the recovery status as a time-dependent variable in the
Cox proportional hazard model. Likewise, we could not
include 4-month and 2-year recovery as two independent
predictors in one model, as a subject would have to be
alive at 2 years in order to have an assessment at that time
and not all patients alive at 4 months were alive at 2 years.
Instead, we assessed early and late recovery separately.
For the 4-month recovery model, the time to event was
calculated from 4-month status assessment; for the 2-year
model, it was calculated starting from 2-year assessment.
The proportional hazard assumptions were tested, and
appropriate diagnostics were performed. Three patients
were censored over the course of long-term follow-up
because of missing information. We included variables
known to correlate with mortality in patients with ICM
as covariates: age, body mass index (BMI), diabetes, sex,
randomisation to CABG versus medical therapy and
OMT. OMT was defined as therapy with aspirin, statin,
beta blocker and ACE inhibitor or angiotensin receptor
blocker at 4 months postrandomisation. Because of low
frequencies, implanted cardiac defibrillator (ICD) and
cardiac resynchronisation therapy (CRT) implantation
variables were excluded from the models. The existing
literature indicates that in the STICH trial CABG was not
independently associated with LVEF improvement but
was associated with mortality.15 To test whether the effect
of LVEF improvement on survival was different for CABG
versus medical therapy, we investigated the interaction
between therapy type and LVEF recovery. The interaction was insignificant for the 4-month time point and the
2-year time point (p values 0.379 and 0.753, respectively),
and therefore was not included in the final models.

Statistical analysis
Baseline clinical data are represented as median with IQR
for continuous variables and as counts with percentages
for categorical data. The McNemar test was used to assess

RESULTS
Patient characteristics
Of the 1212 patients with LVEF ≤35% enroled in the
STICH trial, 932 underwent assessment of LVEF at 4
months and/or 2 years after enrolment. The 932 patients
included in our analysis did not differ significantly from
the STICH population not included in the analysis with
respect to demographics and randomised treatment
assignment to OMT plus CABG or OMT alone, they
had slightly higher prevalence of diabetes (41% vs 33%,
p=0.02) and slightly lower prevalence of CRT (7% vs 11%,
p=0.04, table 1). Among them, 18 patients experienced
normalisation in LVEF (>50%) at 4-
month follow-
up
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In particular, patients with ICM are less likely to experience normalisation in LVEF,5 9 and they are likely to have
focal areas of permanent myocardial damage that are
independent predictors of poor outcome.10 Therefore, it
is unclear whether findings based on cohorts of patients
highly enriched in heart failure of non-ischaemic aetiology apply to patients with ICM and recovered LVEF. It
also remains unclear what prognostic value a normalised
LVEF holds in this patient population.
In order to start filling this gap in knowledge, we analysed data collected in the Surgical Treatment for Ischaemic Heart Failure (STICH) trial. The STICH trial was
designed to compare the benefit of surgical revascularisation with medical therapy to that of medical therapy
alone in patients with ICM and LVEF <35%.8 Patients
were assessed with follow-up echocardiogram at 4 months
and 2 years postrandomisation and were followed for 10
years to assess mortality.11 12

Heart failure and cardiomyopathies

Comorbidity

STICH

Age, mean (SD)
BMI (SD)

60 (9)
27 (5)

61 (9)
27 (5)

59 (9)
27 (5)

0.11
0.06

590 (50)

476 (51)

114 (45)

0.09

1042 (88)

810 (87)

232 (91)

0.07

468 (39)

385 (41)

83 (33)

0.02

28 (11%)
4 (2%)

0.04
0.49

Medical therapy vs CABG, N (%)
Male, N (%)
Diabetes, N (%)
CRT (%)
ICD (%)

92 (8%)
28 (2%)

Included

64 (7%)
24 (3%)

Excluded

P value included vs excluded

Data are presented as mean (SD) for continuous variables and number (percentage) for categorical variables. Patients included and excluded
from the analysis were compared using t-test for continuous variables and χ2 test for categorical variables.
STICH refers to all patients included in the STICH trial. Included refers to subgroup of STICH trial patients who had LVEF assessment during
follow-up and were included in this study. Excluded refers to subgroup of STICH trial patients who did not have LVEF assessment during
follow-up and were excluded from this study. Medical therapy versus CABG refers to patients randomised to medical therapy alone or to
coronary artery bypass graft plus medical therapy.
BMI, body mass index; CABG, coronary artery bypass graft; CRT, cardiac resynchronisation therapy; ICD, permanent implanted cardiac
defibrillator; LVEF, left ventricular ejection fraction; STICH, Surgical Treatment for Ischaemic Heart Failure.

and 35 patients experienced recovery in LVEF (>50%)
at 2 years.
Relationship between LVEF recovery at 4 months and LVEF
recovery at 2 years
A total of 587 patients had LVEF information at both 4
months and 2 years. There was a weak correlation between
LVEF at 4 months and LVEF at 2 years (Spearman correlation 0.56, p<0.0001). However, there was no consistency
in LVEF recovery status between 4 months and 2 years
(McNemar test p=0.0005, figure 1). Of 11 patients who
had recovered LVEF at 4 months and had a 2-year LVEF
measurement, only three continued to have LVEF >50%
at 2 years (right upper quadrant in figure 1).

Figure 1 Relationship between LVEF at 4 months and LVEF
at 2 years: each patient with LVEF measurements at both
4 months and 2 years is represented on the plot as a dot.
Red lines mark LVEF=50% and identify four quadrants. The
lower left quadrant includes patients with LVEF <50% at
both 4 months and 2 years, the upper left quadrant includes
patients with LVEF >50% at 2 years but <50% at 4 months,
the upper right quadrant includes patients with LVEF
>50% at both time points and the lower right quadrant
includes patients with LVEF >50% at 4 months and LVEF
<50% at 2 years. The dots are grouped along the diagonal,
suggesting correlation between LVEF at 4 months and LVEF
at 2 years. However, the number of dots in the right upper
quadrant is much lower than the number of dots in the upper
left quadrant + lower right quadrant indicating significant
disagreement between LVEF recovery at 4 months and LVEF
recovery at 2 years (McNemar test p=0.00047). LVEF, left
ventricular ejection fraction.
Schiffer WB, et al. Open Heart 2021;8:e001528. doi:10.1136/openhrt-2020-001528

Relationship between LVEF recovery at 4 months and mortality
A total of 885 patients had LVEF measurements at 4
months. These 885 patients did not differ significantly
from the patients who did not have LVEF measurement
at 4 months with respect to demographics, comorbidities
and randomisation to OMT plus CABG or OMT alone
(online supplemental table 1). Of these 885 patients,
18 were found to have recovered LVEF, while 867 were
found to have reduced LVEF. Patients with recovered
LVEF at 4 months were similar to patients with reduced
LVEF in terms of age, gender, BMI, prevalence of ICDs or
CRT and randomisation group within the STICH trial but
had a trend towards higher prevalence of diabetes that
was statistically insignificant (66.7% vs 41.1%, p=0.052,
table 2). LVEF recovery at 4 months was not associated
with reduced all-
cause mortality during follow-
up in
unadjusted analysis (Kaplan-
Meyer log-
rank p=0.54,
figure 2) or in the Cox proportional hazards model (HR:
0.93; 95% CI: 0.48 to 1.80; p=0.82; table 3).
3
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Table 1 Comparison between patients with LVEF assessment (included in this study) and patients without LVEF assessment
(excluded from this study)

Open Heart

Age (SD)
BMI (SD)
Medical therapy vs
CABG (%)

LVEF ≤50%
at 4 months
(n=867)

LVEF >50%
at 4 months
(n=18)

P value

60.57 (9.29)
27.43 (4.71)

60.81 (8.02)
27.93 (3.91)

0.915
0.654

449 (51.8)

6 (33.3)

0.189

Male gender (%)

755 (87.1)

13 (72.2)

0.136

Diabetes (%)

356 (41.1)

12 (66.7)

0.052

CRT=Yes (%)

57 (6.6)

3 (16.7)

0.117

567 (65.4)
22 (2.5)

12 (66.7)
0 (0.0)

OMT
ICD

1
1

Data presented as mean (SD) for continuous variables and number
(percentage) for categorical variables. Patients with and without
recovered LVEF at 4 months were compared using t-test for
continuous variables and χ2 test for categorical variables.
Medical therapy versus CABG refers to patients randomised to
medical therapy alone or to CABG plus medical therapy. OMT
refers to patient on OMT at 4 months follow-up.
BMI, body mass index; CABG, coronary artery bypass graft; CRT,
cardiac resynchronisation therapy; ICD, permanent implanted
cardiac defibrillator; LVEF, left ventricular ejection fraction; OMT,
optimal medical therapy.

Relationship between LVEF recovery at 2 years and mortality
A total of 1116 patients survived for at least 2 years. Of these,
634 patients had LVEF measurements at 2 years and were
therefore included in the analysis of survival post 2-
year

Table 3 Relationship between LVEF recovery at 4 months
and mortality
HR (CI)

P value

LVEF recovery at 4 months
Age, per decade

0.93 (0.48 to 1.80)
1.37 (1.24 to 1.51)

0.82
<0.0001

Medical therapy vs CABG

1.45 (1.21 to 1.73)

<0.0001

OMT

0.82 (0.68 to 0.98)

0.031

Diabetes

1.29 (1.08 to 1.54)

0.006

Female gender
BMI

0.61 (0.46 to 0.82)
1.00 (0.98 to 1.02)

0.001
0.828

Cox proportional hazard model of the relationship between LVEF
recovery at 4 months and mortality during follow-up. For each
variable, the HR for mortality during follow-up after adjusting for all
other listed variables is indicated. 95% CI for the HR is reported
in parentheses. Medical therapy vs CABG refers to patients
randomised to medical therapy alone or to CABG plus medical
therapy. OMT refers to patient on OMT at 4 months follow-up.
BMI, body mass index; CABG, coronary artery bypass graft; LVEF,
left ventricular ejection fraction; OMT, optimal medical therapy.

landmark. These patients were less likely to be male (85.5%
vs 91.5%, p=0.04) but did not differ from the rest of the
cohort with respect to other demographics, comorbidities and randomisation to OMT plus CABG or OMT alone
(online supplemental table 2). Of these 634 patients, 35
were found to have recovered LVEF, while 599 were found to
have reduced LVEF. Patients with recovered LVEF at 2 years
were similar to patients with reduced LVEF in terms of age,
BMI, prevalence of ICDs, prevalence of CRT, prevalence of
diabetes and randomisation group within the STICH trial but
were less likely to be male (71.4% vs 86.3%, p=0.03, table 4).
Table 4 Comparison between patients with and without
LVEF recovery at 2 years
LVEF ≤50%
at 2 years
(n=599)

LVEF >50%
at 2 years
(n=35)

P value

60.22 (9.28)
27.48 (4.54)

61.02 (6.65)
27.46 (6.01)

0.616
0.977

Medical therapy vs
CABG (%)

308 (51.4)

13 (37.1)

0.142

Male gender (%)

517 (86.3)

25 (71.4)

0.029

Diabetes (%)

Age (SD)
BMI (SD)

Figure 2 Association between LVEF recovery at 4 months
and mortality survival probability for patients LVEF >50% at 4
months is depicted in red, survival probability of patients with
LVEF <50% at 4 months is depicted in black. For each year
mark on the X-axis the number of subjects at risk in the two
groups is reported above the axis, LVEF <50% on top, LVEF
>50% on the bottom. Kaplan-Meier log-rank test p=0.54.
LVEF, left ventricular ejection fraction.

4

242 (40.4)

20 (57.1)

0.075

CRT (%)

39 (6.5)

1 (2.9)

0.717

OMT (%)
ICD (%)

404 (67.4)
13 (2.2)

26 (74.3)
0 (0.0)

0.512
1

Data presented as mean (SD) for continuous variables and
number (percentage) for categorical variables. Patients with and
without recovered LVEF at 2 years were compared using t-test for
continuous variables and χ2 test for categorical variables. OMT
refers to patient on OMT at 4 months follow-up.
BMI, body mass index; CABG, coronary artery bypass graft; CRT,
cardiac resynchronisation therapy; ICD, permanent implanted
cardiac defibrillator; LVEF, left ventricular ejection fraction; OMT,
optimal medical therapy.
Schiffer WB, et al. Open Heart 2021;8:e001528. doi:10.1136/openhrt-2020-001528
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Table 2 Comparison between patients with and without
LVEF recovery at 4 months

Heart failure and cardiomyopathies

Recovery of LVEF at 2 years was associated with a reduction
in all-cause mortality during follow-up, both in unadjusted
survival analysis (log-rank p=0.004, figure 3) and in the in
the multivariate Cox proportional hazards model (HR: 0.41;
95% CI: 0.21 to 0.80; p=0.009; table 5).
DISCUSSION
We performed a non-prespecified analysis of the STICH
trial, the only contemporary randomised treatment trial
Table 5 Relationship between LVEF recovery at 2 years
and mortality
HR (CI)

P value

LVEF recovery at 2 years
Age, per decade

0.41 (0.21 to 0.80)
1.36 (1.20 to 1.54)

0.009
<0.0001

Female gender

0.57 (0.39 to 0.83)

0.003

Diabetes

1.24 (0.99 to 1.55)

0.066

Medical therapy vs CABG

1.44 (1.14 to 1.80)

0.002

BMI
OMT

1.00 (0.97 to 1.03)
0.95 (0.74 to 1.20)

0.947
0.652

Cox proportional hazard model of the relationship between LVEF
recovery at 2 years and mortality during follow. For each variable,
the HR for mortality during follow-up after adjusting for all other
listed variables is indicated. 95% CI for the HR is reported
in parentheses. Medical therapy vs CABG refers to patients
randomised to medical therapy alone or to CABG plus medical
therapy. OMT refers to patient on OMT at 4 months follow-up.
Statistical testing performed using Cox proportional hazard model.
BMI, body mass index; CABG, coronary artery bypass graft; OMT,
optimal medical therapy.
Schiffer WB, et al. Open Heart 2021;8:e001528. doi:10.1136/openhrt-2020-001528
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Figure 3 Association between LVEF recovery at 2 years
and mortality. survival probability for patients LVEF >50% at
2 years is depicted in red, survival probability of patients with
LVEF <50% at 4 months is depicted in black. For each year
mark on the X-axis the number of subjects at risk in the two
groups is reported above the axis, LVEF <50% on top, LVEF
>50% on the bottom. Kaplan-Meier log-rank test p<0.01.
LVEF, left ventricular ejection fraction.

of patients with ischaemic heart failure. We found that
in patients with ICM: (1) recovery of LVEF at short-term
follow-up (4 months) does not correlate with recovery of
LVEF at long-term follow-up(figure 1); (2) normalisation
of LVEF in the short-term might not be a meaningful
prognostic marker(figure 2, table 3); (3) Normalisation
of LVEF at long-term (2 years) follow-up correlates with
a reduced hazard of death (figure 3, table 4). These findings expand our current understanding of LVEF normalisation in patients with ICM and are relevant to clinical
practice.
Many patients with HFrEF of non-ischaemic aetiology
experience a significant improvement in LVEF in the first
year as a response to OMT. This improvement is typically
an intermediate state before a subsequent deterioration and very seldom (if at all) marks the beginning of
a permanent normalisation of LVEF.15 Patients with ICM
tend to experience less improvement in LVEF than those
with non-ischaemic disease, and seldom recover LVEF in
the normal range.5 9 16 Data on LVEF trajectory in patients
with normalised LVEF and ICM is nearly absent. In this
study, we confirmed that normalisation of LVEF is a rare
occurrence in patients with ICM. In addition, we found
that while LVEF at short-
term follow-
up (4 months)
following initiation of therapy correlated with LVEF at
long-term follow-up (2 years), there was no correlation
between early and late normalisation in LVEF. This is a
novel and unexpected finding. LVEF is typically used as
a surrogate of myocardial function, but is a measure that
incorporates multiple cardiovascular factors, including
preload, afterload (effective arterial elastance), inotropy
(LV end-systolic elastance) and left ventricular stiffness.17
Accordingly, changes in different cardiovascular and
haemodynamic parameters can result in an improvement
in LVEF without an improvement in intrinsic myocardial
contractile function. This is exemplified by the observation that treatment with negative inotropic agents such
as beta-blockers can improve EF as early as 2 weeks after
initiation of therapy.18 We therefore hypothesise that,
in response to medical therapy, some patients with ICM
may experience changes in several cardiovascular factors
that affect LVEF, and that this might result in rapid, but
ephemeral, improvement of LVEF to a normal range.
We found that normalisation in LVEF at 4 months was
not associated with decreased mortality during follow-up,
while normalisation in LVEF at 2 years was associated with
mortality improvement. The observation of a correlation
between recovered LVEF at 2 years and reduced mortality
is novel because the literature reports no data on the
prognostic significance of LVEF normalisation in patients
with ICM, though it does parallel findings in cohorts of
patients with non-ischaemic disease.3–7 19–21 The observation that rapid recovery in LVEF does not correlate with
improved survival is both novel and unexpected insofar
as normalisation in LVEF has been, to date, uniformly
considered a positive prognostic factor.3 5 Patients with
normalised LVEF at 4 months had a modest increase
in the prevalence of diabetes of borderline statistical

Open Heart

Limitations
A strength of this study is that it is the first to examine EF
normalisation in patients with ICM. It is also the first to
investigate the prognostic significance of normalised EF
using clinical trial data. However, our work has several
limitations that should be acknowledged. First, the echocardiographic measurements of LVEF collected in the
STICH trial were not all obtained with the same method.
It has been previously determined that the mean absolute
differences between LVEF as determined by different
echocardiographic methods in the STICH trial were
minimal (mean absolute difference 2.7% for biplane
and visual, 3.0% for single plane and visual and 2.9% for
biplane and single plane),23 but we cannot exclude the
possibility that these small differences biased our findings. Second, normalisation of LVEF in patients with ICM
is a rare event and therefore the number of patients with
recovered LVEF that we analysed is small. These small
numbers might reduce the reliability of our conclusions.
Third, LVEF at 4 months was measured at 4 months from
randomisation and not at 4 months from institution of
therapy.24 Because some patients in the STICH trial experienced a delay between randomisation and initiation
of therapy,11 the timing of this early assessment of LVEF
normalisation might be inaccurate. Fourth, management
of HFrEF has, to some extent, changed since the STICH
trial and therefore our findings might not completely
apply to contemporary patient cohorts. Fifth, while we
know what classes of medications patients were on at 4
months postdischarge, we do not know the exact doses
prescribed. Lastly, as with any non-prespecified secondary
analysis of subgroup of patients within trial populations,
our study should be considered as hypothesis generating
and our findings will need to be confirmed in other
studies.
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Supplementary Table 1. Comparison of Patients with and without LVEF Assessment at 30
Days
30-Day
LVEF
Available (N=885)
Age (SD)
60.58 (9.26)
BMI (SD)
27.44 (4.70)
Medical Therapy vs 455 (51.4)
CABG (%)
Male Gender (%)
768 (86.8)
Diabetes (%)
368 (41.6)
CRI (%)
60 (6.8)
OMT (%)
579 (65.4)
ICD (%)
22 (2.5)

No 30-Day LVEF p-value
(N=47)
59.46 (9.80)
0.42
26.91 (5.14)
0.449
21 (44.7)
0.453
42 (89.4)
17 (36.2)
4 (8.5)
33 (70.2)
2 (4.3)

0.772
0.56
0.557
0.606
0.344

BMI= body mass index; Medical therapy vs CABG= patients randomized to medical therapy
alone or to coronary artery bypass graft plus medical therapy; CRI= cardiac resynchronization
therapy; OMT= patient on optimal medical therapy at 30 days follow-up; ICD= permanent
implanted cardiac defibrillator. Data presented as mean (standard deviation) for continuous
variables and number (percentage) for categorical variables. Statistical testing performed using ttest for continuous variables and the Chi-square test or Fisher’s Exact Test for categorical
variables.
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Supplementary Table 2. Comparison of Patients with and without LVEF Assessment at 2
Years
2-Year
LVEF
Available (N=634)
Age (SD)
60.26 (9.16)
BMI (SD)
27.48 (4.63)
Medical Therapy vs 321 (50.6)
CABG (%)
Male Gender (%)
542 (85.5)
Diabetes (%)
262 (41.3)
CRI (%)
40 (6.3)
OMT (%)
430 (67.8)
ICD (%)
13 (2.1)

No LVEF at
Years (N=201)
59.94 (9.14)
27.30 (5.00)
96 (47.8)
184 (91.5)
72 (35.8)
11 (5.5)
127 (63.2)
5 (2.5)

2 p
0.665
0.639
0.53
0.036
0.192
0.738
0.258
0.78

BMI= body mass index; Medical therapy vs CABG= patients randomized to medical therapy
alone or to coronary artery bypass graft plus medical therapy; CRI= cardiac resynchronization
therapy; OMT= patient on optimal medical therapy at 30 days follow-up; ICD= permanent
implanted cardiac defibrillator. Data presented as mean (standard deviation) for continuous
variables and number (percentage) for categorical variables. Statistical testing performed using ttest for continuous variables and the Chi-square test or Fisher’s Exact Test for categorical
variables.
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